Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

25.67 -0.42 (-1.61%)
Streaming Delayed Price Updated: 2:15 PM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
An Overview of Agios Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
 
Via Benzinga
News headline image
Analyst Ratings For Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Agios (AGIO) Q2 Revenue Jumps 45% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss ↗
Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease... 
Via Chartmill
News headline image
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years ↗
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results. 
Via Benzinga
News headline image
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Earnings Preview: Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
4 Analysts Have This To Say About Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug ↗
The company is currently seeking approval for its thalassemia treatment in four regions. 
Via Investor's Business Daily
News headline image
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides ↗
Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary... 
Via Benzinga
News headline image
Expert Ratings For Agios Pharmaceuticals ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? ↗
Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of... 
Via Benzinga
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Nvidia Again Boosts Nasdaq To Record Highs ↗
The Nasdaq Composite Index is extending Friday's record highs, with help from Nvidia, which is up 5% at last glance and marking its own all-time highs. 
Via Talk Markets
Topics Stocks
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.